affiliate disclosure · We earn affiliate commission on some vendor links. Audits, scores, and rankings are independent — vendors do not pay for placement and do not see drafts. read more →

Same lab, different mechanism

Both compounds come out of Eli Lilly's metabolic-disease research pipeline. Tirzepatide is the older, FDA-approved compound; retatrutide is the next-generation candidate currently in Phase 3.

The difference that matters: tirzepatide hits two receptors (GLP-1 and GIP), while retatrutide hits three (GLP-1, GIP, and glucagon). The third receptor — glucagon — is what produces both the larger weight-loss effect and the still-being-characterized side-effect profile.

Trial outcomes

Phase 2 retatrutide showed 24% mean body-weight reduction at 48 weeks at the highest dose, compared to 20–22% for tirzepatide at peak doses in the Surmount trials. The retatrutide curve also continued sloping down past the typical plateau, which is a notable departure from earlier GLP-1 compounds.

What this means for buyers

Retatrutide is not FDA-approved. It's available in the research-peptide market but the buyer pool is much smaller and quality variance between vendors is higher. Tirzepatide is the safer choice if you want established cross-vendor comparison data; retatrutide is the choice if you specifically want the triple-agonist mechanism.